Total Tumor Volume Should be Considered as an Important Prognostic Factor for Synchronous Multiple Gastric Cancer Patients with Curative Gastrectomy

Abstract Tumour-stroma ratio (TSR) is a novel potential prognostic factor in cancers and based on the proportions of stroma and tumour area. The prognostic value of TSR in gastric cancer is incompletely known. The aim of this study was to estimate prognostic significance of TSR in gastric adenocarcinoma. A search of PubMed (MEDLINE), Web of Science, EMBASE, Cochrane and Scopus databases was performed. A meta-analysis was conducted on five-year survival in gastric cancer patients using inverse variance random-effects methods. The literature search yielded 5329 potential titles, of which a total of seven studies were eligible. Results of six studies including a total of 1779 patients were pooled in the meta-analysis. Only 23 (1.3%) of the patients received neoadjuvant therapy. All six studies had a cut-off of 50% for the proportion of stroma when dividing the patients into low- and high stroma groups. Low TSR (high amount of stroma) was strongly associated with increased five-year mortality (hazard ratio 2.19, 95% CI 1.69–2.85). In conclusion, TSR is a strong prognostic factor in gastric cancer. It could be used to estimate prognosis of gastric cancer patients not receiving neoadjuvant chemotherapy. Further studies including patients receiving neoadjuvant therapy are recommended.

Download Full-text

KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients

Journal of Cancer ◽

10.7150/jca.27899 ◽

2019 ◽

Vol 10 (4) ◽

pp. 821-828 ◽

Cited By ~ 4

Author(s):

Xin-Hui Fu ◽

Zhi-Ting Chen ◽

Wen-Hui Wang ◽

Xin-Juan Fan ◽

Yan Huang ◽

...

Keyword(s):

Gastric Cancer ◽

Prognostic Factor ◽

Cancer Patients ◽

Adverse Prognostic Factor ◽

Gastric Cancer Patients

Download Full-text

Increasing Nodal Ratio is a Poor Prognostic Factor for Survival in Stage III-IV (M0) Gastric Cancer Patients Who Received Curative Surgery Followed by Adjuvant Chemotherapy: A Retrospective Study

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyq215 ◽

2010 ◽

Vol 41 (2) ◽

pp. 245-252 ◽

Cited By ~ 5

Author(s):

J.-S. Kim ◽

M.-A. Kim ◽

D.-Y. Oh ◽

S.-H. Lee ◽

D.-W. Kim ◽

...

Keyword(s):

Gastric Cancer ◽

Retrospective Study ◽

Adjuvant Chemotherapy ◽

Prognostic Factor ◽

Cancer Patients ◽

Stage Iii ◽

Curative Surgery ◽

Poor Prognostic Factor ◽

Nodal Ratio ◽

Gastric Cancer Patients

Download Full-text

Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality Therapy

Journal of Gastrointestinal Cancer ◽

10.1007/s12029-015-9699-y ◽

2015 ◽

Vol 46 (2) ◽

pp. 131-137 ◽

Cited By ~ 14

Author(s):

Drexell Hunter Boggs ◽

Andrew Hanna ◽

Whitney Burrows ◽

Naomi Horiba ◽

Mohan Suntharalingam

Keyword(s):

Esophageal Cancer ◽

Prognostic Factor ◽

Cancer Patients ◽

Gross Tumor Volume ◽

Tumor Volume ◽

Locally Advanced ◽

Advanced Esophageal Cancer ◽

Trimodality Therapy ◽

Important Prognostic Factor ◽

Locally Advanced Esophageal Cancer

Download Full-text

The vascular endothelial growth factor as a predictive and prognostic factor in patients with advanced gastric cancer treated with docetaxel, cisplatin, and 5-florouracil (DCF) regimen.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e15191 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e15191-e15191

Author(s):

Sedef H. Aktas ◽

Hakan Akbulut ◽

Ozan Yazici ◽

Nurullah Zengin ◽

Nalan Akgun ◽

...

Keyword(s):

Gastric Cancer ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Prognostic Factor ◽

Advanced Gastric Cancer ◽

Cancer Patients ◽

Predictive Marker ◽

Vascular Endothelial ◽

Gastric Cancer Patients ◽

Endothelial Growth Factor

e15191 Background: Vascular endothelial growth factor (VEGF) is a key element stimulating the angiogenesis in solid tumors. In the current study, we aimed to assess the role of plasma VEGF levels as a prognostic and predictive marker for advanced gastric cancer patients treated with a modified docetaxel, cisplatinum and 5-florouracil (DCF) regimen. Methods: Thirty consecutive patients treated with a modified DCF regimen were included in the study. The plasma VEGF levels of the patients before treatment and following two cycles of chemotherapy were assayed. Results: The modified DCF regimen was well tolerated and yielded a median overall survival (OS) time of 9,0 months and 2-year OS rate of 20%. Good performance status, lower pre-treatment VEGF levels,and decrease in VEGF levels following chemotherapy were found to be independent prognostic factors for OS. Conclusions: The results of the current study suggest that the corrected plasma levels of VEGF could be used as a prognostic factor for advanced gastric cancer patients and a decrease in VEGF levels following 2 cycles of chemotherapy as a predictive marker for patients receiving DCF chemotherapy regimen.

Download Full-text